CN118234499A - 用于黄病毒治疗的2′-氯代-2′-氟代-n2-氨基-n6-甲氨基嘌呤核苷酸 - Google Patents

用于黄病毒治疗的2′-氯代-2′-氟代-n2-氨基-n6-甲氨基嘌呤核苷酸 Download PDF

Info

Publication number
CN118234499A
CN118234499A CN202280073609.4A CN202280073609A CN118234499A CN 118234499 A CN118234499 A CN 118234499A CN 202280073609 A CN202280073609 A CN 202280073609A CN 118234499 A CN118234499 A CN 118234499A
Authority
CN
China
Prior art keywords
compound
use according
virus
administered
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073609.4A
Other languages
English (en)
Chinese (zh)
Inventor
J-P·索玛迪西
A·莫萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atea Pharmaceuticals Inc
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Priority claimed from PCT/US2022/042545 external-priority patent/WO2023034617A1/en
Publication of CN118234499A publication Critical patent/CN118234499A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280073609.4A 2021-09-03 2022-09-02 用于黄病毒治疗的2′-氯代-2′-氟代-n2-氨基-n6-甲氨基嘌呤核苷酸 Pending CN118234499A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240578P 2021-09-03 2021-09-03
US63/240,578 2021-09-03
PCT/US2022/042545 WO2023034617A1 (en) 2021-09-03 2022-09-02 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment

Publications (1)

Publication Number Publication Date
CN118234499A true CN118234499A (zh) 2024-06-21

Family

ID=85380756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073609.4A Pending CN118234499A (zh) 2021-09-03 2022-09-02 用于黄病毒治疗的2′-氯代-2′-氟代-n2-氨基-n6-甲氨基嘌呤核苷酸

Country Status (7)

Country Link
US (1) US20240226131A1 (https=)
EP (1) EP4395787A4 (https=)
JP (1) JP2024533122A (https=)
KR (1) KR20240052801A (https=)
CN (1) CN118234499A (https=)
AU (1) AU2022339679A1 (https=)
CA (1) CA3174107A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018048937A1 (en) * 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Also Published As

Publication number Publication date
CA3174107A1 (en) 2023-03-03
EP4395787A1 (en) 2024-07-10
EP4395787A4 (en) 2025-07-23
US20240226131A1 (en) 2024-07-11
AU2022339679A1 (en) 2024-03-07
JP2024533122A (ja) 2024-09-12
KR20240052801A (ko) 2024-04-23

Similar Documents

Publication Publication Date Title
JP7124024B2 (ja) Ｒｎａウイルス治療に対する２’－置換－ｎ６－置換プリンヌクレオチド
CN112209980B (zh) 取代的嘌呤核苷酸
KR20010102082A (ko) 항바이러스제로서의 포스포르아미데이트, 및 (1ｒ, 시스)-4-(6-아미노-9ｈ-푸린-9-일)-2-시클로펜텐-1-메탄올의 모노-, 디-, 및 트리-포스페이트 에스테르
WO2015101183A1 (zh) 尿嘧啶核苷酸类似物及其制备方法和应用
CN118234499A (zh) 用于黄病毒治疗的2′-氯代-2′-氟代-n2-氨基-n6-甲氨基嘌呤核苷酸
KR102619437B1 (ko) 젬시타빈의 인-함유 프로드러그
WO2023034617A1 (en) 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment
RU2776918C2 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
TW201927312A (zh) 用於治療 Ｃ型肝炎病毒之β－Ｄ－２’－脫氧－２’－α－氟－２’－β－Ｃ－取代－４’－氟－Ｎ－取代－６－胺基－２－取代嘌呤核苷酸

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination